Events

Organized by Clinical Accelerator, a medical device CRO supporting First-in-Human and Early Feasibility studies, the Summit brings together medtech innovators, clinicians, investors, and industry experts to discuss the development and clinical advancement of new medical technologies, with a strong focus on cardiovascular and interventional medicine.

The program centered on one shared question: how can new technologies reach patients in the safest and most efficient way? Companies presented clinical results and development plans, and having clinicians, regulatory experts, and investors in the same room made for open, practical conversations.

Highlights

• Presentation on digital patient twins. On Sunday, Dr. Simon J. Sonntag presented on accelerating and de-risking medical device development with digital patient twins.
• Shark Tank competition. Virtonomy co-sponsored the Shark Tank, where early-stage device companies pitched their innovations to a panel of investors, clinicians, and industry leaders. It brings promising technology, expert feedback, and potential partnerships together in one place.
• A connected ecosystem. Two gala dinners gave attendees time to build relationships beyond the conference sessions.

At Virtonomy, we are dedicated to helping save lives by supporting companies to accelerate development and reduce risks through digital patient twins, and events like this show how closely early clinical evidence and virtual testing can work together.

New York Valves 2026 once again demonstrated why it has become one of the leading meetings in structural heart disease.

Over three days, the cardiovascular community gathered in New York to discuss the latest developments in heart valve therapies, imaging, and device innovation. The program featured late-breaking clinical data, live cases, FDA sessions, and hands-on workshops, highlighting the rapid pace of change in the field.

One theme stood out across many sessions: structural heart care is becoming increasingly personalized. Discussions focused not only on long-term outcomes for transcatheter therapies, but also on how to select the right treatment for the right patient at the right time.

For Virtonomy, it was encouraging to see how naturally topics such as simulation, digital patient twins, and computational modeling fit into these conversations. As devices become more advanced, so do the tools needed to develop and evaluate them. We are already looking forward to next year’s event.

A recurring theme throughout the conference was the increasing complexity and personalization of cardiovascular interventions. As devices and therapies continue to evolve, so does the need for technologies that support their development, evaluation, and clinical adoption. This is where our product v-Patients comes in and offers solutions with digital twins, computer modeling (medical simulations) and combines in silico methods with traditional testing.

EuroPCR 2026 highlighted a clear shift in cardiovascular innovation. While AI, simulation, and digital technologies were once emerging topics, the conversation has now moved toward practical implementation. Across sessions on structural heart interventions, imaging, and next-generation devices, attendees focused on how new technologies can be integrated into clinical and development workflows.

The conference’s emphasis on education, hands-on learning, and collaboration reinforced why EuroPCR remains one of the most influential events in interventional cardiology. For Virtonomy, it was particularly encouraging to see digital patient twins and in-silico methods increasingly recognized as part of the future of cardiovascular device development.